enGene Holdings (ENGN) CDO Jill Buck granted 195,000 stock options

Rhea-AI Filing Summary

enGene Holdings Inc. disclosed that Chief Development Officer Jill Buck received a grant of stock options. On January 30, 2026, she was awarded 195,000 stock options with an exercise price of $9.53 per common share. These options were granted at no cost on the grant date and are held directly. The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company, and represents her total reported derivative holdings after the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Buck Jill

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	195,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 195,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buck Jill

(Last) (First) (Middle)

C/O 4868 RUE LEVY, SUITE 220

(Street)

SAINT-LAURENT A8 H4R 2P1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
enGene Holdings Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.53	01/30/2026		A		195,000		(1)	01/30/2036	Common Shares	195,000	$0	195,000	D

Explanation of Responses:

1. This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.

	/s/ Lee G. Giguere, as attorney-in-fact for the Reporting Person	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did enGene Holdings (ENGN) report for Jill Buck?

enGene Holdings reported that Chief Development Officer Jill Buck received 195,000 stock options on January 30, 2026. The options give her the right to buy common shares at a fixed exercise price over time.

What is the exercise price of Jill Buck’s new stock options at enGene (ENGN)?

The granted stock options have an exercise price of $9.53 per common share. This means Jill Buck can purchase enGene common shares at $9.53 when the options vest and are exercised, subject to the vesting schedule and her continued service.

How many enGene (ENGN) stock options does Jill Buck hold after this transaction?

After this grant, Jill Buck beneficially owns 195,000 stock options in enGene Holdings. All of these options come from the reported award and are held as a direct ownership position according to the filing.

How do Jill Buck’s enGene (ENGN) stock options vest over time?

The options vest monthly in substantially equal amounts over 48 months. Vesting is conditioned on Jill Buck’s continued service with enGene, so she earns the right to exercise portions of the grant gradually over four years.

Is Jill Buck’s stock option award in enGene (ENGN) a purchase or a grant?

The transaction reflects an award of stock options, not a market purchase. The filing shows transaction code “A” and a price of $0 for the derivative, indicating a compensatory grant rather than shares bought on the open market.

What role does Jill Buck hold at enGene Holdings (ENGN) in this Form 4?

In the Form 4, Jill Buck is identified as an officer of enGene Holdings, serving as Chief Development Officer. The reported stock option grant is tied to her position and ongoing service with the company.